Summary of Study ST002179
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001387. The data can be accessed directly via it's Project DOI: 10.21228/M8FB0C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002179 |
Study Title | Impact of nitisinone on the cerebrospinal fluid metabolome of a murine model of alkaptonuria |
Study Summary | Background: Nitisinone induced hypertyrosinaemia is well documented in Alkaptonuria (AKU), and there is uncertainty over whether it may contribute to a decline in cognitive function and or mood by altering neurotransmitter metabolism. The aim of this work was to evaluate the impact of nitisinone on the cerebrospinal fluid (CSF) metabolome in a murine model of AKU, with a view to providing additional insight into metabolic changes that occur following treatment with nitisinone. Methods: 17 CSF samples were collected from BALB/c Hgd-/-mice (n=8, treated with nitisinone – 4 mg/L and n=9, no treatment). Samples were diluted 1:1 with deionised water and analysed using a 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time-of-flight mass spectrometry (Agilent, Cheadle, UK). Raw data were processed using a targeted feature extraction algorithm and an established in-house accurate mass retention time database. Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability. Experimental groups were compared using a moderated t-test with Benjamini-Hochberg false-discovery rate adjustment. Results: Tyrosine, acetyl-tyrosine, γ-glutamyl-tyrosine, p-hydroxyphenylacetic acid and 3-(4-hydroxyphenyl)lactic acid were shown to increase in abundance (log2 fold change 2.6-6.9, 3/5 were significant p<0.05) in the mice that received nitisinone. Several other metabolites of interest were matched but no significant differences were observed, including the aromatic amino acids phenylalanine and tryptophan, and monoamine metabolites adrenaline, 3-methoxy-4-hydroxyphenylglycol and octopamine. Conclusions: Evaluation of the CSF metabolome of a murine model of AKU showed a significant difference in the abundance of a limited number of metabolites. None of these have been reported in CSF from a murine model of AKU previously. Moreover this study confirms that some monoamine metabolites do not appear to be altered following nitisinone therapy. |
Institute | University of Liverpool Institute of Life Course & Medical Sciences |
Last Name | Davison |
First Name | Andrew |
Address | 1. Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; 2. Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK 3. School of Exercise Science, Liverpool John Moores University, Liverpool, UK |
andrew.davison@liverpoolft.nhs.uk | |
Phone | 0151 706 4011 |
Submit Date | 2022-05-13 |
Num Groups | 2 |
Total Subjects | 17 |
Raw Data Available | Yes |
Raw Data File Type(s) | d, mzML |
Analysis Type Detail | LC-MS |
Release Date | 2022-06-08 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment group |
---|---|---|
SA209243 | Hgd81.3 + Nitisinone POS | Nitisinone |
SA209244 | Hgd81.2 + Nitisinone POS | Nitisinone |
SA209245 | Hgd81.1 + Nitisinone POS | Nitisinone |
SA209246 | Hgd82.1 + Nitisinone POS | Nitisinone |
SA209247 | Hgd82.2 + Nitisinone POS | Nitisinone |
SA209248 | Hgd83.2 - No treatment POS | Nitisinone |
SA209249 | Hgd83.1 + Nitisinone POS | Nitisinone |
SA209250 | Hgd81.1 + Nitisinone NEG | Nitisinone |
SA209251 | Hgd80.2 + Nitisinone POS | Nitisinone |
SA209252 | Hgd83.1 + Nitisinone NEG | Nitisinone |
SA209253 | Hgd82.1 + Nitisinone NEG | Nitisinone |
SA209254 | Hgd81.3 + Nitisinone NEG | Nitisinone |
SA209255 | Hgd81.2 + Nitisinone NEG | Nitisinone |
SA209256 | Hgd83.2 - No treatment NEG | Nitisinone |
SA209257 | Hgd82.2 + Nitisinone NEG | Nitisinone |
SA209258 | Hgd81.6 - No treatment POS | No Treatment (control) |
SA209259 | Hgd81.5 - No treatment POS | No Treatment (control) |
SA209260 | Hgd81.4 - No treatment POS | No Treatment (control) |
SA209261 | Hgd82.3 - No treatment POS | No Treatment (control) |
SA209262 | Hgd82.4 - No treatment POS | No Treatment (control) |
SA209263 | Hgd81.6 - No treatment NEG | No Treatment (control) |
SA209264 | Hgd83.4 - No treatment POS | No Treatment (control) |
SA209265 | Hgd83.3 - No treatment POS | No Treatment (control) |
SA209266 | Hgd80.4 - No treatment POS | No Treatment (control) |
SA209267 | Hgd80.3 - No treatment POS | No Treatment (control) |
SA209268 | Hgd83.4 - No treatment NEG | No Treatment (control) |
SA209269 | Hgd80.3 - No treatment NEG | No Treatment (control) |
SA209270 | Hgd80.4 - No treatment NEG | No Treatment (control) |
SA209271 | Hgd83.3 - No treatment NEG | No Treatment (control) |
SA209272 | Hgd81.5 - No treatment NEG | No Treatment (control) |
SA209273 | Hgd82.3 - No treatment NEG | No Treatment (control) |
SA209274 | Hgd82.4 - No treatment NEG | No Treatment (control) |
SA209275 | Hgd81.4 - No treatment NEG | No Treatment (control) |
Showing results 1 to 33 of 33 |